Home    Help    Cart    Login
Get Free Updates on Industry Research and Analysis!


Search all reports:
 Go 


Pharma and Biotech News


Marketing Services
Interested in marketing your information product through us? Email us at helpdesk AT pharma-reports.com

or call 800-304-0345




Topic Suggestion?


 Item Detail
Item Detail
You're Here: Pharmaceutical



Direct to Consumer - Trends and Developments

Select Your Format:
Price: $3,500.00
Shipping: US:  $0.00 
Non-US  $0.00
QTY:
Print Order form to pay by check
Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
GBI Research

This research provides key data, information and analysis of the major issues affecting the stakeholders of the direct to consumer (DTC) advertising market in the US and Europe. It discusses the major changes that have been observed after the relaxation of rules over DTC advertising by the FDA in 1997.

The report also covers the issues specific to the European market (where branded DTC advertising is banned). The report provides a comprehensive view of some of the best examples of DTC advertising along with analysis covering the reasons for such success. The report also provides a detailed analysis of failed examples along with the most important lessons. It also provides an insight into government regulations in the US and Europe covering DTC advertisements and their implications for the marketing strategies of the pharmaceutical companies.

The study provides a detailed explanation of some of the major reasons behind recent developments in the pharmaceutical DTC advertising landscape. At the end, the report touches upon some of the major trends that are likely to shape the future landscape for the DTC advertising market in the US and Europe.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.


Scope

The scope of this report includes:

- Identification and analysis of major issues that are affecting the DTC advertising marketplace in the US and Europe

- Case studies of DTC advertising strategies of Pfizer, AstraZeneca, Merck and Sanofi-Aventis and so on

- Estimation and analysis of potential impact of the issues on the key stakeholders affected by the DTC advertisement market developments

- Analysis of key government regulations in the US and Europe affecting the DTC advertising market

- Future trends that will shape the DTC advertising market in the US and Europe


Reasons to buy

The report will enhance your decision making and will enable you to:

- Develop effective business strategies to tackle the impact of major issues to the key stakeholders in the DTC advertising market

- Understand the DTC advertising strategies that succeeded and failed for the major drugs of key pharmaceutical players

- Ensure success through more effective marketing strategies for the drugs that are to be launched or already in the market

- Identify and exploit the factors that could help to maximize returns on drugs through better advertising

- Optimize your advertising impact through identification of the most suitable medium for your drug

- Develop understanding of the regulatory attitude and hurdles for DTC advertising in the geographies covered in the report

Table of Contents



71 pages

Publication Date : December 2009
 Options
Options
Select Your Format:
 Your Price
Your Price
Price: $3,500.00
Shipping: US:  $0.00 Non-US  $0.00
 QTY: 

Print Order form to pay by check


 Related Items
Related Items
Changing Direct-to-Consumer Advertising Landscape Changing Direct-to-Consumer Advertising Landscape

An effective DTC strategy can catapult a drug into blockbuster status. However, after a 10 year period of skyrocketing DTC budgets, Pharma is now opting for lower cost and more targeted approaches. Pharma faces tighter DTC regulations in the US, while in Europe there may be suggestions that DTC will be employed, but is this likely to work given the differences in culture and market? Scope: - Analysis of a return on investment model for DTC advertising - Case study analysis of DTC and disease awareness ads - Overview of DTC regulation in the US - Overview of patient communication for prescription drugs in Europe Highlights: The more serious a disease, the more life threatening it is for the patient, as a result the patient is more empowered as it is keen to find out new potential treatments for the life-threatening condition.  (MORE)
 

Return policy: We do accept hard copy books if a reason is included. Electronic products including
CD-ROMs and PDF files are non-returnable/non-refundable due to the duplicable nature of these products.

To market your reports, contact us at 800-304-0345 or email
Helpdesk AT PharmaReports DOT com